An interventional study of ATLAS 2030 exoskeleton in Cerebral Palsy, sponsored by MarsiBionics. Completed at 6 sites in Spain. Open to participants aged 3 Years to 14 Years. Per ClinicalTrials.gov, last updated 2024-09-27.
Sponsored by MarsiBionics · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Cerebral Palsy with a site in Spain — 14 open to participants now, 17 under way, 1 of them phase 3. Cerebral Palsy · Spain.
Among the 54 studies in Cerebral Palsy with a site in Spain, this one is the 23rd largest by enrollment of the 44 interventional ones that give a count, is one of 6 that started in 2022, is one of 37 with no phase, and was the 27th registered.
1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.
Browse Cerebral Palsy studies →14 of the 54 studies in Cerebral Palsy with a site in Spain are open now. Recruiting first, the newest first:
Facultat de ciencies de la Salut Universitat Ramon Llull · Sites in Spain
Ages 18–80
University of Valencia · Sites in Spain
Ages 10–18
Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús · Sites in Spain
Ages 3–8
Universidade da Coruña · Sites in Spain
Ages 3–8
Universidad de Almeria · Sites in Spain
Ages 2–11 · Healthy volunteers
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.
This study: 3 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6
First in 2011; this study’s year is marked. 6 started in 2022.
This study's enrollment of 30 is below the median of 34 across 1,434 interventional studies indexed under Cerebral Palsy.
Median enrollment 32 across the 44 interventional studies, 50 across the 10 observational. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 54 have an industry lead sponsor. The 10 most frequent:
MarsiBionics is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
MarsiBionics has 8 studies filed under Cerebral Palsy — fewer than ten, so there is no comparison to draw.
2 of the studies in Cerebral Palsy with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06438666University of MalagaEffects Obtained at Manual Function After Applying Anodic Transcranial Direct Current Stimulation (tCDS) in Children With Spastic Hemiparetic Cerebral Palsy | 2026-12-23 |
| NCT07745712ABLE Human Motion S.L.Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 54 studies in Cerebral Palsy with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to assess the usability and efficacy of receiving therapy with the peaditric exoskeleton ATLAS 2030in children with gait impairment due to a cerebral palsy condition. It will be valued the impact of rehabilitation with the exoskeleton at the physical level on parameters such as joint range, spasticity, as well as the impact in quality of life. It is also assessed the impact at the level of functionality of the participants, through the administration of different functional assessment scales.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The children will continue with their current rehabilitation program
The children will receive 2 hours of exoskeleton ATLAS 2030 gait training a week for 3 months
Device: ATLAS 2030 exoskeleton
Individualized Rehabilitation Treatment with the ATLAS 2030 Exoskeleton consists of the following phases: 1. Telephone contact phase (1 session) 2. Inclusion Phase (1 session) 3. Signing of informed consent (1 session) 4. Initial Evaluation Phase (1 session) 5. Treatment Phase (1st part) (7 sessions) 6. Monthly Evaluation Phase (1 session) 7. Treatment Phase (2nd part) (7 sessions) 8. Monthly Evaluation Phase (1 session) 9. Treatment Phase (3rd part) (7 sessions) 10. Final Evaluation Phase and results (2 sessions)
Gross Motor Function Classification System
To indentify the diffrent levels of the Gross Motor Function Classification System who can use the ATLAS 2030 exoskeleton. The Gross Motor Function Classification System goes from Level 1 (can walk indoors and outdoors and climb stairs without using hands for support; can perform usual activities such as running and jumping; has decreased speed, balance and coordination) to Level 5 (has physical impairments that restrict voluntary control of movement and the ability to maintain head and neck position against gravity; is impaired in all areas of motor function; cannot sit or stand independently, even with adaptive equipment; cannot independently walk, though may be able to use powered mobility)
Time frame: Every month up to 3 months
To quantify number of steps taken within the device
Quantity of steps taken within the exoskeleton
Time frame: Every session up to 28 sessions
Changes in joint range of motion
To evaluate the joint range of motion changes at the hip, knee and ankle after the ATLAS 2030 use measured by goniometer
Time frame: Every session up to 28 sessions
Changes in spasticity
To evaluate spasticity changes at the lower limb muscle groups after ATLAS 2030 use by Modified Asworth Scale
Time frame: Every session up to 28 sessions
Changes in the Six-Minute Walking Test performance
To assess changes in the distance the child can walk in six minutes by using the Six-Minute Walking Test
Time frame: Every month up to three months
Changes in the 10 Meters Walking Test performance
To assess changes in the time needed to walk 10 meters by using the 10 Meters Walking Test
Time frame: Every month up to three months
Changes in the time walked within the device
To assess possible changes in the time walked within the device
Time frame: Three months
Changes in the Gross Motor Function Measure 88 for children with cerebral palsy (GMFM-88)
To evaluate possible changes in the gross motor function after 3 months of ATLAS 2030 use twice a week where a higher score means child´s gross motor function is better
Time frame: Every month up to three months
Changes in the Functional Independence Measure for Children (WeeFim)
To evaluate possible changes in the overall functionality after 3 months of ATLAS 2030 use twice a week by using the Functional Independence Measure for Children where a higher score means the child is more functional, more independant
Time frame: Every month up to three months
Cerebral Palsy Quality of Life
To assess possible changes in the quality of life of the children after using the ATLAS 2030 for 3 months twice a week by using the Cerebral Palsy Quallity of Life scale where a higher percentage means a better quality of life
Time frame: Three months
Safety of the ATLAS 2030
Measured as the occurrence of adverse events such as onset of pain, fatigue, presence of falls or alteration of the integrity of the user's skin, by the use of the device.
Time frame: at study completion
The Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)
To assess both professionals and patients´satisfaction when using the ATLAS 2030
Time frame: at study completion
Acceptability
Measured through the dropout rate of the participants.
Time frame: at study completion
Accessibility
Measure such as the relationship between the number of patients recruited and potential patients who were not recruited
Time frame: at study completion
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Jun 2023, 8 months.
Of 925 interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MarsiBionics